MGMT Protein Expression Predicts Effectiveness Of Brain Cancer Chemotherapy

Wednesday, July 2, 2014 - 05:40 in Health & Medicine

Researchers have identified a biomarker that predicts whether glioblastoma – the most common form of primary brain cancer – will respond to chemotherapy.   "Every patient diagnosed with glioblastoma is treated with a chemotherapy called temozolomide. About 15 percent of these patients derive long-lasting benefit," said Clark C. Chen, MD, PhD, vice-chairman of Academic Affairs, Division of Neurosurgery, UC San Diego School of Medicine and the study's principal investigator. "We need to identify which patients benefit from temozolomide and which another type of treatment. All therapies involve risk and the possibility of side-effects. Patients should not undergo therapies if there's no likelihood of benefit." read more

Read the whole article on Scientific Blogging

More from Scientific Blogging

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net